An integrated pharmacokinetic-pharmacodynamic (PKPD) modeling analysis of trastuzumab emtansine (T-DM1)-induced thrombocytopenia (TCP) and hepatotoxicity in patients with HER2–positive metastatic breast cancer

Brendan Bender,Angelica Quartino,Chunze Li,Shang-Chiung Chen,Melanie Smitt,Alexander Strasak,Natalia Chernyukhin,Bei Wang,Jin Jin,Sandhya Girish,Lena E. Friberg

An integrated pharmacokinetic-pharmacodynamic (PKPD) modeling analysis of trastuzumab emtansine (T-DM1)-induced thrombocytopenia (TCP) and hepatotoxicity in patients with HER2–positive metastatic breast cancer

2016

Brendan Bender
Angelica Quartino
Chunze Li
Shang-Chiung Chen
Melanie Smitt
Alexander Strasak
Natalia Chernyukhin
Bei Wang
Jin Jin
Sandhya Girish
Lena E. Friberg

An integrated pharmacokinetic-pharmacodynamic (PKPD) modeling analysis of trastuzumab emtansine (T-DM1)-induced thrombocytopenia (TCP) and hepatotoxicity in patients with HER2–positive metastatic breast cancer

Keywords:

Pharmacology
Pharmacodynamics
Trastuzumab emtansine
Medicine
Pharmacokinetics
Metastatic breast cancer
pharmacokinetic pharmacodynamic
Oncology
in patient
Internal medicine
Pharmaceutical sciences

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations